The clearance applies to patients with HR-positive, HER2-negative advanced breast cancer carrying an ESR1 mutation, a biomarker associated with tumors developing resistance to standard therapies. Known chemically as giredestrant, the selective estrogen receptor degrader prolonged the time before disease progression in the evERA trial. The regulatory milestone reinforces Roche's longstanding oncology footprint established via its subsidiary Genentech and the legacy drug Herceptin.
Key points
Roche anticipates that the newly authorized breast cancer medication could eventually bec…: Roche anticipates that the newly authorized breast cancer medication could eventually become its top-selling product.
The presence of the targeted ESR1 gene mutation indicates a patient's cancer is resisting…: The presence of the targeted ESR1 gene mutation indicates a patient's cancer is resisting conventional treatments.
The regulatory clearance helps Roche defend its market position against intensifying onco…: The regulatory clearance helps Roche defend its market position against intensifying oncology competition from rival drugmakers.
Sources checked by our analysis pipeline: 1
The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever.
The approval of Wilserdly, also known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology.
The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. The evERA trial showed that the drug, an oral treatment known as a selective estrogen receptor degrader, or SERD, extended the time period before patients’ tumors progressed.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Rising costs across the medical sector are directly driving up coverage expenses for enrolled seniors. Under the newly adjusted rates, beneficiaries must absorb an extra $6.50 charge each month, elevating standard payments to $209.40. This upward shift reflects the growing financial pressures placed on the federal insurance program by expanded healthcare delivery.
The Advertising Standards Authority acted against promotional campaigns that exaggerated everyday symptoms like fatigue and mood changes to sell private blood tests. Regulators found that the marketing relied on unsupported statistics to exploit consumer anxieties regarding ageing and hormone deficiency. This enforcement reflects a broader regulatory crackdown on online medical providers marketing hormonal diagnostic services.
Ahead of a scheduled spring 2027 restriction on platforms like TikTok and Instagram for under-16s, researchers are mobilizing across England, Scotland, and Wales to measure the real-world fallout. Funded by The Wellcome Trust, academic teams will analyze whether drastically altering digital environments actually improves wellbeing or simply encourages teenagers to bypass restrictions. The resulting data will directly inform international online safety frameworks facing similar regulatory debates.